Monopar Therapeutics Files 8-K

Ticker: MNPR · Form: 8-K · Filed: 2024-04-10T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Monopar filed a routine 8-K, no major news.

AI Summary

Monopar Therapeutics Inc. filed an 8-K on April 10, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific details on financial performance or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a routine disclosure for Monopar Therapeutics, indicating the submission of required financial statements and exhibits to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any new material events or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Monopar Therapeutics?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as required by the SEC.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing was on April 10, 2024.

In which state is Monopar Therapeutics Inc. incorporated?

Monopar Therapeutics Inc. is incorporated in Delaware.

What is the address of Monopar Therapeutics' principal executive offices?

The address of Monopar Therapeutics' principal executive offices is 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.

Does this filing announce any specific new business developments or financial results?

This filing does not explicitly announce specific new business developments or detailed financial results; it primarily serves as a notification of required disclosures and exhibits.

From the Filing

0001437749-24-011573.txt : 20240410 0001437749-24-011573.hdr.sgml : 20240410 20240410080039 ACCESSION NUMBER: 0001437749-24-011573 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240410 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 24834287 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20240402_8k.htm FORM 8-K mnpr20240402_8k.htm false 0001645469 0001645469 2024-04-10 2024-04-10     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 10, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒           Item 7.01   Regulation FD Disclosure.     On April 10, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) is now active and recruiting patients with advanced cancers.   The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.     Item 9.01 Financial Statements and Exhibits   Exhibit No.      Description 99.1   Press Release Dated April 10, 2024 104   Cover Page I

View on Read The Filing